Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

SIMPLE SUMMARY: The current standard of care for patients with HER2-positive early breast cancer who have a pathological complete response after neoadjuvant HER2-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. However, it is not clear how long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Swain, Sandra M., Macharia, Harrison, Cortes, Javier, Dang, Chau, Gianni, Luca, Hurvitz, Sara A., Jackisch, Christian, Schneeweiss, Andreas, Slamon, Dennis, Valagussa, Pinuccia, du Toit, Yolande, Heinzmann, Dominik, Knott, Adam, Song, Chunyan, Cortazar, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599862/
https://www.ncbi.nlm.nih.gov/pubmed/36291835
http://dx.doi.org/10.3390/cancers14205051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599862/
https://www.ncbi.nlm.nih.gov/pubmed/36291835
http://dx.doi.org/10.3390/cancers14205051

Ejemplares similares